List of Excipients in Branded Drug HYCODAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genus Lifesciences Inc	HYCODAN	hydrocodone bitartrate and homatropine methylbromide	64950-205	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Genus Lifesciences Inc	HYCODAN	hydrocodone bitartrate and homatropine methylbromide	64950-205	LACTOSE MONOHYDRATE
Genus Lifesciences Inc	HYCODAN	hydrocodone bitartrate and homatropine methylbromide	64950-205	MAGNESIUM STEARATE

HYCODAN Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 7, 2026

HYCODAN is a legacy oral antitussive containing hydrocodone bitartrate and homatropine methylbromide. Its commercial value is driven by formulation execution, controlled-substance compliance, supply reliability, and brand recognition rather than meaningful new-drug exclusivity. The strongest opportunities are differentiated oral liquids, sugar-free presentations, improved palatability, unit-dose packaging, and compliant generic or authorized-generic supply. The principal barriers are opioid scheduling, abuse diversion, pediatric safety requirements, and the limited clinical differentiation of a mature product.

What is HYCODAN and which formulations are marketed?

HYCODAN combines hydrocodone, an opioid agonist, with homatropine methylbromide, an anticholinergic included to discourage excessive ingestion. The product is used as an antitussive for coughs where opioid therapy is considered appropriate. FDA labeling warns about respiratory depression, misuse, addiction, accidental ingestion, and potentially fatal overdose, particularly in children [1].

Historically, HYCODAN has been supplied in two principal oral dosage forms:

Dosage form	Active ingredients	Key excipient strategy	Commercial relevance
Tablets	Hydrocodone bitartrate and homatropine methylbromide	Conventional compressed-tablet excipients, including fillers, binder, disintegrant, lubricant, and glidant	Low manufacturing complexity; exposed to generic substitution
Oral solution or syrup	Hydrocodone bitartrate and homatropine methylbromide	Sweeteners, flavoring agents, viscosity modifiers, preservatives, pH adjusters, colorants, and cosolvents	Greater formulation and patient-acceptance opportunity; higher stability and dosing risks

The precise inactive-ingredient composition depends on the marketed label and manufacturer. FDA-approved labeling identifies conventional tablet excipients and, for liquid products, a combination of sucrose or other sweetening components, glycerin or propylene glycol, flavoring, preservatives, and buffering agents [1,2].

What excipient strategy is used in HYCODAN tablets?

HYCODAN tablets use a conventional immediate-release solid oral formulation. The functional excipient architecture generally includes:

• A diluent such as lactose or microcrystalline cellulose to provide tablet mass.
• Pregelatinized starch or another disintegrant to promote breakup after administration.
• Povidone or a comparable polymeric binder to improve granulation and tablet strength.
• Magnesium stearate as a lubricant.
• Colloidal silicon dioxide as a glidant and flow aid.

This design is technically undifferentiated. The primary development priorities are content uniformity at low opioid loading, tablet hardness, friability, disintegration, dissolution, and resistance to manufacturing variability.

Hydrocodone products create a particular content-uniformity challenge because the active dose is small relative to the tablet mass. Homatropine methylbromide also must be distributed consistently. A manufacturer pursuing an ANDA or other abbreviated pathway would need to control blend segregation, lubricant overmixing, granulation endpoint, and tablet compression force.

A conventional tablet platform offers limited room for premium pricing. Its main commercial advantages are low cost, mature supply chains, simple packaging, and broad pharmacy familiarity. A new tablet product would need either lower acquisition cost, reliable availability, a different strength, or a meaningful packaging or adherence advantage.

What excipient strategy is used in HYCODAN oral liquid?

The liquid formulation has greater commercial potential because excipients directly affect taste, dosing accuracy, microbial stability, and patient acceptance.

Sweeteners and palatability

Sucrose can improve taste but creates concerns for patients with diabetes, pediatric use, dental exposure, and caloric intake. A sugar-free alternative could use combinations of sorbitol, glycerin, sucralose, sodium saccharin, or other permitted sweeteners. The formulation must control aftertaste because hydrocodone and homatropine can produce a strong medicinal profile.

A successful sugar-free product would need comparable or better palatability without increasing gastrointestinal adverse effects. High polyol concentrations can cause osmotic gastrointestinal symptoms. Sweetener selection also affects viscosity, density, preservative performance, and fill-volume accuracy.

Flavor systems

Flavor is a central differentiator. Fruit flavors can mask bitterness but may increase pediatric appeal, which creates a safety concern for an opioid-containing product. Packaging and labeling should avoid unnecessary child-directed positioning. A restrained adult-oriented flavor system may be commercially safer than a highly attractive confectionary profile.

Flavor compatibility must be evaluated under accelerated and long-term stability conditions. Interactions with preservatives, pH adjusters, bottle materials, and oxygen exposure can alter taste and potency.

Preservatives and pH control

An oral liquid requires a validated microbial-control strategy. Sodium benzoate, benzoic acid, or another suitable preservative may be used depending on pH, concentration, container closure, and regulatory precedent. Buffering agents such as citrate salts can stabilize pH, but the buffer system can affect preservative activity and the solubility of formulation components.

The target pH must balance:

• Hydrocodone and homatropine chemical stability.
• Preservative effectiveness.
• Taste.
• Container compatibility.
• Dose uniformity throughout shelf life.

Preservative efficacy testing, microbial limits, extractables and leachables, and in-use stability are important development requirements.

Cosolvents and viscosity modifiers

Glycerin and propylene glycol can improve mouthfeel, dissolve flavor components, and influence viscosity. Excessive cosolvent concentrations can create tolerability issues and raise regulatory scrutiny, particularly in pediatric populations.

Viscosity should support accurate measurement without making the product difficult to pour or draw into an oral syringe. A liquid that pours too freely increases dosing risk. A liquid that is too viscous can retain drug on the container wall and reduce dose recovery.

What formulation patents protect HYCODAN?

HYCODAN is a mature product with no evident commercial dependence on a modern formulation-patent estate. The original product predates the contemporary Hatch-Waxman patent system by decades, and any original composition or formulation protection would have expired long ago.

The relevant commercial rights should be separated into four categories:

Protection category	HYCODAN position
Original composition patent	No practical current protection expected for the legacy active combination
Formulation patent	No clearly material, current formulation barrier is established by the core FDA product information
Method-of-use patent	Any original therapeutic-use protection would be expected to have expired
Regulatory exclusivity	No meaningful new-drug exclusivity is expected for a legacy product of this age

The Orange Book should be reviewed for the current reference-listed drug, NDA 005213 or the applicable listed HYCODAN presentation, and any patents actually submitted by the NDA holder [3]. A patent listing would not automatically establish broad market protection. It would need to be evaluated for claim scope, expiration, enforceability, pediatric extensions, and whether the listed patent covers the proposed generic product or method of use.

When does HYCODAN lose exclusivity?

HYCODAN’s practical exclusivity has already expired. The product’s remaining protection is primarily commercial and regulatory:

1. Trademark and brand recognition.
2. Product-specific manufacturing know-how.
3. Controlled-substance registration and distribution controls.
4. FDA approval of particular strengths and dosage forms.
5. Customer relationships and reliable supply.
6. Potential private-label or authorized-generic arrangements.

A generic manufacturer could pursue an ANDA if the reference product and dosage form support that pathway. A formulation materially different from the listed product could require a 505(b)(2) application rather than a conventional ANDA, depending on the change and the reference product data package [4].

Are there Paragraph IV challenges to HYCODAN?

No material current Paragraph IV litigation or settlement structure is apparent from the core FDA product materials cited here. That is consistent with a legacy opioid combination whose original protection is no longer commercially significant.

A new Paragraph IV dispute would be more likely to involve a later-added patent covering a particular liquid formulation, delivery device, abuse-deterrent system, or manufacturing process. It would not normally arise from the basic HYCODAN tablet composition.

For a prospective entrant, the relevant diligence sequence is:

• Identify the current reference-listed product.
• Check Orange Book patent listings.
• Review FDA approval dates and dosage forms.
• Search Federal Court and PTAB records for later formulation or method patents.
• Analyze any applicable controlled-substance manufacturing and distribution restrictions.

Does HYCODAN have biosimilar risk?

No. HYCODAN is a small-molecule oral drug, not a biologic. Biosimilar pathways do not apply. Competitive entry would occur through generic, authorized-generic, 505(b)(2), or potentially state-regulated private-label channels.

The principal substitution risk is generic erosion. Pharmacies and payers can substitute an approved generic hydrocodone-homatropine product where state law and prescription requirements permit.

What commercial opportunities exist for HYCODAN excipients?

Sugar-free oral solution

A sugar-free product could address diabetes-conscious patients, reduce dental concerns, and create a differentiated label. The opportunity is strongest if taste, viscosity, stability, and preservative performance match or exceed the established product.

Alcohol-free formulation

An alcohol-free liquid may appeal to institutional buyers, pediatric settings, and patients avoiding ethanol. The formulation challenge is replacing alcohol’s solvent and flavor functions without compromising stability or palatability.

Unit-dose packaging

Unit-dose cups, oral syringes, or sealed pouches could reduce dosing errors and diversion opportunities. Unit-dose packaging also fits hospitals, long-term-care facilities, correctional systems, and specialty pharmacies. The tradeoff is higher packaging cost and more complex controlled-substance reconciliation.

Tamper-evident and diversion-resistant packaging

Packaging cannot eliminate opioid abuse, but it can improve inventory control and make unauthorized opening more visible. Child-resistant closures, serialized labels, limited-volume bottles, and integrated oral syringes have potential commercial value.

Improved dose-measurement systems

An oral syringe supplied with a liquid product can improve dosing accuracy compared with household spoons. The device must be compatible with the solution, deliver the labeled volume consistently, and avoid retention or adsorption of hydrocodone.

Private-label and contract manufacturing

The product is suitable for a manufacturer with DEA registration, controlled-substance security systems, validated analytical methods, and established pharmacy distribution. Contract manufacturing and private-label supply may offer better returns than launching a heavily branded product because the core drug is mature and clinically familiar.

What manufacturing and intellectual-property barriers affect entry?

The largest barriers are operational rather than patent-based.

A manufacturer must manage Schedule II controlled-substance requirements for hydrocodone-containing products, including procurement quotas, physical security, recordkeeping, suspicious-order monitoring, serialization where applicable, and DEA compliance [5]. The precise scheduling and regulatory obligations should be assessed against the applicable product strength and current federal rules.

Liquid manufacturing creates additional risks:

• Hydrocodone assay and degradation-product control.
• Homatropine methylbromide content uniformity.
• Preservative effectiveness.
• Microbial control.
• Accurate fill volume.
• Container-closure compatibility.
• Stability after opening.
• Flavor and color consistency.
• Child-resistant packaging.

These controls can create a meaningful barrier for smaller entrants even when patents do not.

How strong is the HYCODAN patent estate?

The patent estate is weak as a source of current exclusionary power. The product is old, the active combination is established, and the commercial opportunity does not depend on a surviving core composition patent.

The strongest protectable elements for a new entrant would be narrow and formulation-specific:

• A novel low-sugar or sugar-free liquid system.
• A preservative and buffer combination with demonstrated stability.
• A taste-masking composition.
• A dose-metering closure or integrated delivery device.
• A tamper-evident controlled-substance package.
• A manufacturing process that improves uniformity or shelf life.
• A distinct abuse-deterrent formulation, if technically and clinically justified.

Such patents would face written-description, obviousness, enablement, and design-around risks. Formulation claims must show a measurable technical advantage rather than merely restating routine excipient substitutions.

What is the FDA regulatory status of HYCODAN?

HYCODAN is an FDA-regulated prescription opioid antitussive. FDA labeling imposes warnings relating to respiratory depression, misuse, addiction, neonatal opioid withdrawal, accidental ingestion, and use in children [1].

A tablet that matches the reference product may be suitable for an ANDA. A new oral liquid with a different sweetener system, preservative system, concentration, flavor, or delivery device may require a more fact-specific regulatory analysis. A 505(b)(2) pathway may be appropriate where the product relies partly on FDA findings for an approved reference but includes material formulation or delivery changes [4].

Because the product contains hydrocodone, FDA approval is only one part of launch readiness. DEA registration, controlled-substance security, quota planning, distribution controls, and postmarketing pharmacovigilance are central commercial requirements.

How does HYCODAN compare with competing cough products?

HYCODAN competes with other opioid and non-opioid prescription antitussives, including dextromethorphan-containing products, benzonatate, and hydrocodone-acetaminophen products used for cough in some historical markets. It also competes with nonprescription cough products.

Competitive factor	HYCODAN	Non-opioid antitussives	Hydrocodone-acetaminophen products
Opioid exposure	Yes	Usually no	Yes
Acetaminophen exposure	No	No	Yes
Controlled-substance burden	High	Lower or absent	High
Formulation differentiation	Mainly liquid excipients and packaging	Broad OTC flavor and dosage options	Primarily analgesic positioning
Generic substitution risk	High	High	High
Commercial opportunity	Specialty liquid, supply reliability, packaging	Convenience and OTC positioning	Pain and cough market segmentation

HYCODAN’s absence of acetaminophen can be a prescribing consideration, but its hydrocodone content creates significant safety and compliance obligations.

What generic launch scenarios exist for HYCODAN?

The most plausible launch scenarios are:

1. A conventional immediate-release tablet generic competing on price and supply.
2. A generic oral solution matching the reference concentration and excipient profile.
3. A sugar-free or alcohol-free liquid using an ANDA or 505(b)(2) strategy, depending on formulation differences.
4. An authorized generic or private-label product supplied by the brand owner or an approved manufacturer.
5. A unit-dose institutional presentation with controlled dispensing and improved inventory management.

The tablet opportunity is easier to manufacture but more vulnerable to price erosion. The liquid opportunity has greater technical risk but offers more room for differentiation and channel-specific contracting.

Key Takeaways

• HYCODAN contains hydrocodone bitartrate and homatropine methylbromide.
• Its core composition and therapeutic-use protection are legacy rights with no expected current exclusivity value.
• The commercial patent estate is weak unless a later formulation, packaging, device, or manufacturing patent applies.
• Oral liquids offer more excipient-driven differentiation than tablets.
• Sugar-free, alcohol-free, taste-masked, unit-dose, and dose-metered products are the clearest commercial opportunities.
• Controlled-substance compliance is a larger entry barrier than core patent protection.
• Generic entry risk is high for conventional tablets and materially lower only where a differentiated liquid or delivery system creates regulatory and manufacturing complexity.
• Biosimilar risk does not apply because HYCODAN is a small-molecule drug.
• FDA pathway selection depends on how closely the proposed product matches the reference-listed product.
• Reliable supply, controlled distribution, stability, palatability, and packaging are likely to determine commercial success.

FAQs About HYCODAN Excipient and Commercial Strategy

Can HYCODAN be reformulated without changing the active ingredients?

Yes. Excipients, flavor, preservative system, sweetener, concentration, and packaging can be changed, but the regulatory pathway depends on the extent of the changes and the reference product.

Is a sugar-free HYCODAN formulation commercially attractive?

Yes, if it achieves acceptable taste, preservative performance, viscosity, and stability. Sugar-free positioning can differentiate the product but does not remove opioid-related regulatory obligations.

Can a new HYCODAN formulation receive patent protection?

Potentially. Protection would need to cover a non-obvious and technically supported formulation, delivery device, packaging system, or manufacturing process. Routine excipient substitutions are vulnerable to obviousness challenges.

Does HYCODAN require abuse-deterrent technology?

No universal requirement mandates an abuse-deterrent HYCODAN formulation. A manufacturer may develop diversion-resistant packaging or a more resistant dosage form, but the added cost and regulatory burden must be justified by market demand.

Is HYCODAN suitable for pediatric commercialization?

Pediatric opioid use presents substantial safety and regulatory constraints. Any pediatric-oriented commercial strategy would require careful dosing, labeling, packaging, risk management, and FDA review. Attractive flavors and child-directed presentation create avoidable safety concerns.

References

1. U.S. Food and Drug Administration. (n.d.). HYCODAN (hydrocodone bitartrate and homatropine methylbromide) prescribing information. DailyMed.
2. National Library of Medicine. (n.d.). Hycodan: Hydrocodone bitartrate and homatropine methylbromide tablet and oral solution labeling. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
5. U.S. Drug Enforcement Administration. (2024). Controlled substances and registration requirements for manufacturers and distributors.